IGHV gene rearrangements as outcome predictors for CLL patients: Experience of Ukrainian group

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1093-1101

  Kryachok, I ^a   Abramenko, I ^b   Bilous, N ^b   Chumak, A ^b   Martina, Z ^b   Filonenko, I ^b  

^a NATIONAL CANCER INSTITUTE   (Ukraine)

^b Research Central for Radiation Medicine   (Ukraine)

Author keywords

Chronic lymphocytic leukaemia; IGHV gene mutational status; IGHV gene usage; Prognosis; Stereotyped B cell receptors

Indexed keywords

B LYMPHOCYTE RECEPTOR; BERBERINE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; PHENANTHRIDINE DERIVATIVE; UKRAIN;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HEMOLYTIC ANEMIA; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STEREOTYPY; TREATMENT OUTCOME; UKRAINE; AGED; CANCER STAGING; COHORT ANALYSIS; FOLLOW UP; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BERBERINE ALKALOIDS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE REARRANGEMENT; GENES, IMMUNOGLOBULIN HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENANTHRIDINES; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; SURVIVAL RATE;

EID: 84866298534     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9872-5     Document Type: Article

References (49)

1. Fedorenko ZP, Gaysenko AV, Gulak LO, et al. Cancer in Ukraine, 2007-2008. Bulletin of National Cancer-registry of Ukraine. 2009;10:104.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
3. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-84.
4. Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23(1):25-47.
5. Rassenti LZ, Jain S, Keating MJ, et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008;112(5):1923-30.
6. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-34.
7. Binet JL, Auguier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariante survival analysis. Cancer. 1981;48:198-205.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-7.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-54.
10. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-6.
11. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 2002;99:2262-4.
12. Potter KN, Orchard J, Critchley E, et al. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood. 2003;101:3082-4.
13. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3 s: implicating recognition of a common antigen epitope. Blood. 2003;101: 4952-7.
14. Tobin G, Rosenquist R. Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol. 2005;22(3): 217-28.
15. Ghia EM, Jain S, Widhopf GF 2nd, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008;111(10):5101-8.
16. Oscier D, Wade R, Davis Z, et al. Prognostic factors identify 3 risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica. 2010;95(10):1705-12.
17. Bomben R, Dal-Bo M, Benedetti D, et al. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res. 2010;16(2):620-8.
18. Tschumper RC, Geyer SM, Campbell ME, et al. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest. 2008; 118(1):306-15.
19. Forconi F, Cencini E, Rossi D, et al. IGHV1-69/D3-16/J3 subset 6 is associated with indolent disease course of early stage CLL (Rai 0) independent of unmutated status. Haematologica. 2010; 95(S2):43.
20. Chu CC, Catera R, Zhang L, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115(19):3907-15.
21. Orlandi EM, Zibellini S, Pascutto C, et al. IGHV unmutated status influences outcome more than IGHV1-69 gene usage per se in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma. 2009;9(5):390-3.
22. Ghia P, Stamatopoulos K, Belessi C, et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood. 2005;105(4):1678-85.
23. Tomomatsu J, Isobe Y, Oshimi K, et al. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behaviour. Leuk Lymphoma. 2010;51(12): 2230-9.
24. Bianchi S, Moreno P, Landoni AI, et al. Immunoglobulin heavy chain V-D-J gene rearrangement and mutational status in Uruguayan patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(11):2070-8.
25. Hojjat-Farsangi M, Jeddi-Tehrani M, Razavi SM, et al. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukaemic B cells in Iranian patients with chronic lymphocytic leukemia. Cancer Sci. 2009;100(12): 2346-53.
26. Bilous N, Bomben R, Dal Bo M, et al. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leuk Lymphoma. 2010;51(5): 822-38.
27. Bomben R, Dal BM, Capello D, et al. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. Br J Haematol. 2009;144:492-506.
28. Messmer BT, Raphael BJ, Aerni SJ, et al. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res. 2009;33: 368-76.
29. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111:1524-33.
30. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109:259-70.
31. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-7.
32. Visco C, Ruggeri M, Evangelista ML, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008;111(3):1110-6.
33. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
34. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-317.
35. Abramenko I, Bilous N, Chumak A, et al. Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident-with focus on immunoglobulin heavy chain gene analysis. Leuk Res. 2008;32:535-45.
36. Kabat EA, Wu TT, Perry HM. Sequences of proteins of immunological interest. Darby: Diane Publishing Company; 1992.
37. Thompson JD, Gibson TJ, Plewniak F, et al. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 1997;25:4876-82.
38. Catera R, Silverman GJ, Hatzi K, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008;14(11-12):665-74.
39. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111(7):3838-48.
40. Visco C, Novella E, Peotta E, et al. Autoimmune haemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica. 2010;95(7):1230-2.
41. Efremov DG, Ivanovski M, Siljanovski N, et al. Restricted immunoglobulin VH region repertoire in chronic lymphocytic leukemia patients with autoimmune haemolytic anemia. Blood. 1996;87:3869-78.
42. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune haemolytic anemia. Leukemia Lymphoma. 2007;48:1072-80.
43. Galletti J, Canones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune haemolytic anemia. J Immunol. 2008;181:3674-83.
44. Mittal S, Blaylock MG, Culligan DJ, et al. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica. 2008;93: 151-2.
45. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007;139(3):398-404.
46. Smit LA, van Maldegem F, Langerak AW, et al. Antigen receptors and somatic hypermutation in B-cell chronic lymphocytic leukemia with Richter's transformation. Haematologica. 2006;91(7):903-11.
47. Timár B, Fülöp Z, Csernus B, et al. Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. Leukemia. 2004;18(2): 326-30.
48. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009; 15(13):4415-22.
49. Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202-15.